CRISPR Therapeutics Founding Scientist, Emmanuelle Charpentier Awarded 2015 Breakthrough Prize In Life Sciences

BASEL, Switzerland--(BUSINESS WIRE)--CRISPR Therapeutics, a biopharmaceutical company focused on the gene-editing technology CRISPR-Cas9, today announced that Dr Emmanuelle Charpentier, a co-founder and advisor to the Company, has been awarded the 2015 Breakthrough Prize in Life Sciences. Dr Charpentier, head of the Regulation in Infection Biology department at the Helmholtz-Zentrum für Infektionsforschung (Helmholtz Centre for Infection Research) in Braunschweig, Germany, was honored for her pioneering work in the development of the CRISPR-Cas9 genome-editing tool.

CRISPR-Cas9 is an innovative gene-editing technology that can be used to edit the genomes of organisms directly with surgical precision. It can be used to specifically target a diseased gene and either delete or correct it. Dr Charpentier co-invented the CRISPR-Cas9 technology while working at Umea University in Sweden.

Help employers find you! Check out all the jobs and post your resume.

Back to news